. 2021 Jul 8;40(3):949–982. doi: 10.1007/s10555-021-09976-0

Table 4.

Incidence of all-grade endocrine adverse events in cancer patients treated with ICI [66, 71, 74–78]

Drugs/irAE	Anti-PD-1/PD-L1	Anti-CTLA-4	Combined treatment
Thyroid dysfunction	5–10% [74] 5–10% [75] 8.6–10.1% [76] 19% [77]	1–5% [74] 1–5% [75] 1.5–15.2% [76] 7% [77]	15.0% [76] 20.0% [75] 28–50% [77]
Hypothyroidism	7.0–8.3% [78] 8.6% [66]	2.8% [78] 4.2% [66]	13.2% [71] 15.0% [66] 16.3–16.4% [78]
Hyperthyroidism	3.0–3.3% [78]	0.6% [71] 0.9% [78]	8% [71] 10.2–11.1% [78]
Hypophysitis	0.4–0.7% [76] 0.5% [75] <1% [77]	1–16% [71] 2.3–6.5% [76] 2.6–4.1% [78] 3.2–17% [77] 3.9% [75]	7.7% [75] 11.7% [76]

Drugs/irAE

Anti-PD-1/PD-L1

Anti-CTLA-4

Combined treatment

Thyroid dysfunction

5–10% [74]

5–10% [75]

8.6–10.1% [76]

19% [77]

1–5% [74]

1–5% [75]

1.5–15.2% [76]

7% [77]

15.0% [76]

20.0% [75]

28–50% [77]

Hypothyroidism

7.0–8.3% [78]

8.6% [66]

2.8% [78]

4.2% [66]

13.2% [71]

15.0% [66]

16.3–16.4% [78]

Hyperthyroidism

3.0–3.3% [78]

0.6% [71]

0.9% [78]

8% [71]

10.2–11.1% [78]

Hypophysitis

0.4–0.7% [76]

0.5% [75]

<1% [77]

1–16% [71]

2.3–6.5% [76]

2.6–4.1% [78]

3.2–17% [77]

3.9% [75]

7.7% [75]

11.7% [76]